Retatrutide is a synthetic peptide comprising 39 amino acids that acts as a triple agonist for the glucagon receptor, glucagon-like peptide-1 receptor, and gastric inhibitory polypeptide receptor. Retatrutide shows promise as a treatment for obesity, type 2 diabetes, and non-alcoholic fatty liver disease due to its ability to regulate appetite and enhance insulin secretion while suppressing glucagon production.